Due to the coronavirus disease 2019 (COVID-19), researchers all over the world have tried to find an appropriate therapeutic approach for the disease. The angiotensin-converting enzyme 2 (ACE2) has been shown as a necessary receptor to cell fusion, which is involved in infection due to severe acute respiratory syndrome-coronavirus 2 (SARS-CoV). It is commonly crucial for all organs and systems. When ACE2 is down-regulated via the SARS-CoV-2 spike protein, it results in the angiotensin II (Ang II)/angiotensin type 1 receptor axis overactivation. Ang II has harmful effects, which can be evidenced by dysfunctions in many organ experienced by COVID-19 patients. ACE2 is the SARS-CoV-2 receptor and has an extensive distribution; thus, some COVID-19 cases experience several symptoms and complications. We suggest strategy for the potential protective effect of ACE2 to the viral infection. The exciting potential of hrs ACE2 as a protective measure against viral infections, including COVID-19, has been revealed in recent research. It is suggested that sACE2 has additional effectiveness on the lungs and different organs. The development of human recombinant soluble ACE2, also known as human recombinant soluble ACE2 (hrsACE2), aims to reduce lung injury and prevent multiple organ dysfunction. This is achieved by competing with membrane-bound ACE2, thereby reducing the SARS-CoV-2 entrance into target cells. In addition, the growth of SARS-CoV-2 virus is significantly decreased by approximately 1000-5000 times in cell culture, engineered human blood vessels, and kidney organoids upon administration of the engineered hrsACE2. While these findings hold great promise, further investigation is crucial to fully explore the therapeutic possibilities of this innovative approach.